The CFO of EKSO BIONICS (NASDAQ: EKSO) is Buying SharesBy Carrie Williams
Following this transaction Max Scheder-Bieschin’s holding in the company was increased by 11.34% to a total of $253K. In addition to Max Scheder-Bieschin, one other EKSO executive reported Buy trades in the last month.
The company has a one year high of $6.38 and a one year low of $3.45. Currently, EKSO BIONICS has an average volume of 44.83K. The Company has a book value per share of 10.6601.
Starting in March 2015, EKSO received 5 Buy ratings in a row.
Ekso Bionics Holdings, Inc. designs, develops and sells wearable bionic human exoskeletons that have applications in healthcare, industrial, military, and consumer markets. The company operates through Engineering Services and Medical business segments. The Engineering services segment engages in research and development service arrangements, technology license agreements, and government grants. The Medical service segment designs, engineers, and manufactures exoskeletons for applications in the medical and military markets. The company was founded on January 30, 2012 and is headquartered in Richmond, CA.